Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations-Reference-Cited by-同舟云学术

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations

Published:2019-01-05 Issue:11 Volume:144 Page:2887-2896
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Lin Yen‐Ting¹²^ORCID,Chen Jin‐Shing³,Liao Wei‐Yu²,Ho Chao‐Chi²,Hsu Chia‐Lin²,Yang Ching‐Yao²,Chen Kuan‐Yu²,Lee Jih‐Hsiang⁴,Lin Zhong‐Zhe⁵^ORCID,Shih Jin‐Yuan²,Yang James Chih‐Hsin⁵⁶,Yu Chong‐Jen²^ORCID

Affiliation:

1. Graduate Institute of Clinical MedicineNational Taiwan University College of Medicine Taipei Taiwan

2. Department of Internal Medicine, National Taiwan University Hospital and College of MedicineNational Taiwan University Taipei Taiwan

3. Department of Surgery, National Taiwan University Hospital and College of MedicineNational Taiwan University Taipei Taiwan

4. Department of OncologyNational Taiwan University Hospital Hsin‐Chu Branch Hsin‐Chu Taiwan

5. Department of OncologyNational Taiwan University Hospital Taipei Taiwan

6. Graduate Institute of OncologyNational Taiwan University College of Medicine Taipei Taiwan

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32025

Reference48 articles.

1. Cancer statistics, 2018

2. Beyond ALK‐RET, ROS1 and other oncogene fusions in lung cancer;Kohno T;Transl Lung Cancer Res,2015

3. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

4. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular docking, QSAR, and simulation analyses of EGFR-targeting phytochemicals in non-small cell lung cancer;Journal of Molecular Structure;2025-02

2. Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure;Journal of the Formosan Medical Association;2024-08

3. Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database;Clinical Lung Cancer;2024-06

4. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer;Archives of Toxicology;2024-03-05

5. Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC;Therapeutic Advances in Medical Oncology;2024-01